Nothing Special   »   [go: up one dir, main page]

SK11562003A3 - Nové spirotricyklické deriváty a ich použitie ako inhibítorov fosfodiesterázy-7 - Google Patents

Nové spirotricyklické deriváty a ich použitie ako inhibítorov fosfodiesterázy-7 Download PDF

Info

Publication number
SK11562003A3
SK11562003A3 SK1156-2003A SK11562003A SK11562003A3 SK 11562003 A3 SK11562003 A3 SK 11562003A3 SK 11562003 A SK11562003 A SK 11562003A SK 11562003 A3 SK11562003 A3 SK 11562003A3
Authority
SK
Slovakia
Prior art keywords
dihydro
cyclohexane
lower alkyl
chloro
quinazolin
Prior art date
Application number
SK1156-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Patrick Bernardelli
Pierre Ducrot
Edwige Lorthiois
Fabrice Vergne
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK11562003(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of SK11562003A3 publication Critical patent/SK11562003A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SK1156-2003A 2001-03-21 2002-03-18 Nové spirotricyklické deriváty a ich použitie ako inhibítorov fosfodiesterázy-7 SK11562003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2001/003355 WO2002076953A1 (fr) 2001-03-21 2001-03-21 Nouveaux derives spirotricycliques et utilisation de ces derives en tant qu'inhibiteurs de la phosphodiesterase-7
PCT/EP2002/003594 WO2002074754A1 (fr) 2001-03-21 2002-03-18 Nouveaux derives spirotricycliques et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase-7

Publications (1)

Publication Number Publication Date
SK11562003A3 true SK11562003A3 (sk) 2005-01-03

Family

ID=8164349

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1156-2003A SK11562003A3 (sk) 2001-03-21 2002-03-18 Nové spirotricyklické deriváty a ich použitie ako inhibítorov fosfodiesterázy-7

Country Status (47)

Country Link
US (3) US20020198198A1 (fr)
EP (2) EP1801106A3 (fr)
JP (1) JP4086663B2 (fr)
KR (1) KR100617435B1 (fr)
CN (1) CN100447136C (fr)
AP (1) AP1699A (fr)
AR (1) AR033617A1 (fr)
AT (1) ATE367381T1 (fr)
AU (1) AU2002304800B2 (fr)
BG (1) BG108181A (fr)
BR (1) BR0208192A (fr)
CA (1) CA2441313C (fr)
CU (1) CU23218A3 (fr)
CY (1) CY1106829T1 (fr)
CZ (1) CZ20032451A3 (fr)
DE (1) DE60221233T2 (fr)
DK (1) DK1373224T3 (fr)
EA (1) EA006815B1 (fr)
EC (1) ECSP034750A (fr)
EE (1) EE200300459A (fr)
ES (1) ES2288552T3 (fr)
GE (1) GEP20053631B (fr)
GT (1) GT200200053A (fr)
HK (1) HK1061854A1 (fr)
HR (1) HRP20030740A2 (fr)
HU (1) HUP0303637A3 (fr)
IL (2) IL157659A0 (fr)
IS (1) IS2529B (fr)
MA (1) MA27001A1 (fr)
MX (1) MXPA03008485A (fr)
MY (1) MY142045A (fr)
NO (1) NO326086B1 (fr)
NZ (1) NZ527847A (fr)
OA (1) OA12454A (fr)
PA (1) PA8541601A1 (fr)
PE (1) PE20021010A1 (fr)
PL (1) PL367058A1 (fr)
PT (1) PT1373224E (fr)
RS (1) RS50429B (fr)
SI (1) SI1373224T1 (fr)
SK (1) SK11562003A3 (fr)
SV (1) SV2003000925A (fr)
TN (1) TNSN03076A1 (fr)
TW (1) TWI267509B (fr)
UA (1) UA74243C2 (fr)
WO (2) WO2002076953A1 (fr)
ZA (1) ZA200306601B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400244A1 (fr) 2002-09-17 2004-03-24 Warner-Lambert Company LLC Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase
GB0230195D0 (en) * 2002-12-24 2003-02-05 Biofocus Plc Compound Libraries
EP2617419A1 (fr) 2003-04-24 2013-07-24 Incyte Corporation Dérivés d'aza-spiro-alcanes utilisés comme inhibiteurs de métalloprotéases
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
CN1835753A (zh) * 2003-08-12 2006-09-20 弗·哈夫曼-拉罗切有限公司 作为促皮质释放素(cfr)拮抗剂的螺-取代的四氢喹唑啉
EP2433943B1 (fr) 2004-07-01 2013-09-11 Daiichi Sankyo Company, Limited Intermédiaires pour dérivés de thiénopyrazole ayant une activité inhibitrice de la PDE7
GB0504209D0 (en) * 2005-03-01 2005-04-06 Pfizer Ltd New use of PDE7 inhibitors
WO2006092692A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
WO2006092691A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation des inhibiteurs de pde7 pour le traitement de la douleur neuropathique
KR100680497B1 (ko) * 2005-07-25 2007-02-08 엘지전자 주식회사 근거리통신 시스템에서 단말기가 액세스 포인트에 접속하는방법
EP1928437A2 (fr) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP2258357A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
JP2009517453A (ja) 2005-12-02 2009-04-30 ファイザー・リミテッド Pde7阻害剤としてのスピロ環式キナゾリン誘導体
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101917992A (zh) * 2007-03-27 2010-12-15 奥默罗斯公司 用于治疗运动障碍的pde7抑制剂的用途
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CA2687944A1 (fr) * 2007-05-24 2008-11-27 Pfizer Limited Derives spirocycliques
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
CN107375296A (zh) 2010-11-08 2017-11-24 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2986610B9 (fr) 2013-04-19 2018-10-17 Incyte Holdings Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA3008689A1 (fr) * 2015-12-16 2017-06-22 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Analogue de pyrido[1,2-a]pyrimidone, sa forme cristalline, son intermediaire et son procede de preparation
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107382976A (zh) * 2017-07-04 2017-11-24 孙秀芹 一种治疗盆腔炎的化合物及制备方法和应用
MX2020000295A (es) * 2017-07-12 2020-07-22 Dart Neuroscience Llc Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7.
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
IL312465A (en) 2018-05-04 2024-06-01 Incyte Corp FGFR inhibitor solid forms and processes for their preparation
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環
WO2024038089A1 (fr) 2022-08-18 2024-02-22 Mitodicure Gmbh Utilisation d'un agent thérapeutique ayant une activité inhibitrice de phosphodiestérase-7 pour le traitement et la prévention de maladies associées à la fatigue, à l'épuisement et/ou à l'intolérance à l'effort chroniques

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815979A (ja) 1981-07-11 1983-01-29 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体およびその製造法
US4764512A (en) 1986-08-27 1988-08-16 Rorer Pharmaceutical Corporation Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
HUT72076A (en) 1992-12-11 1996-03-28 Merck & Co Inc Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
US5602143A (en) * 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
KR19990064276A (ko) * 1995-10-17 1999-07-26 니콜라스 피터 비가르트 (니크 비가르트), 콜린 레드롭 제약학적으로 활성인 퀴나졸린 화합물
CN1205008A (zh) * 1996-08-30 1999-01-13 协和发酵工业株式会社 咪唑并喹唑啉衍生物
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
WO2000066164A1 (fr) 1999-05-04 2000-11-09 American Home Products Corporation Compositions contraceptives contenant des agents antiprogestatifs et progestatifs
WO2000066560A1 (fr) * 1999-05-04 2000-11-09 American Home Products Corporation Derives de quinazolinone et de benzoxazine tenant lieu de modulateurs du recepteur de progesterone
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
WO2001045707A1 (fr) 1999-12-21 2001-06-28 Merck & Co., Inc. Inhibiteurs de prenyl-proteine transferase
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
IS2529B (is) 2009-07-15
HUP0303637A3 (en) 2004-07-28
AP1699A (en) 2006-12-26
US20070049558A1 (en) 2007-03-01
NO20034187L (no) 2003-10-15
HUP0303637A2 (hu) 2004-03-01
CN100447136C (zh) 2008-12-31
OA12454A (en) 2004-09-30
DK1373224T3 (da) 2007-10-15
CU23218A3 (es) 2007-07-20
RS50429B (sr) 2009-12-31
PE20021010A1 (es) 2003-02-01
PL367058A1 (en) 2005-02-21
CZ20032451A3 (cs) 2004-09-15
CY1106829T1 (el) 2012-05-23
TNSN03076A1 (fr) 2005-12-23
NO326086B1 (no) 2008-09-15
GT200200053A (es) 2003-02-12
HK1061854A1 (en) 2004-10-08
EA006815B1 (ru) 2006-04-28
JP4086663B2 (ja) 2008-05-14
MY142045A (en) 2010-08-30
KR20030086315A (ko) 2003-11-07
US20020198198A1 (en) 2002-12-26
AU2002304800B2 (en) 2007-08-30
ZA200306601B (en) 2004-08-25
EA200300906A1 (ru) 2004-02-26
CA2441313A1 (fr) 2002-09-26
CN1498212A (zh) 2004-05-19
CA2441313C (fr) 2009-03-31
YU74003A (sh) 2006-05-25
MA27001A1 (fr) 2004-12-20
WO2002074754A1 (fr) 2002-09-26
ES2288552T3 (es) 2008-01-16
UA74243C2 (uk) 2005-11-15
EP1373224B1 (fr) 2007-07-18
US20040214843A1 (en) 2004-10-28
ATE367381T1 (de) 2007-08-15
BG108181A (en) 2004-09-30
NO20034187D0 (no) 2003-09-19
DE60221233T2 (de) 2008-04-03
JP2004529123A (ja) 2004-09-24
HRP20030740A2 (en) 2005-06-30
IS6934A (is) 2003-08-29
TWI267509B (en) 2006-12-01
SV2003000925A (es) 2003-05-20
MXPA03008485A (es) 2003-12-08
US7214676B2 (en) 2007-05-08
EP1801106A3 (fr) 2007-07-04
PA8541601A1 (es) 2003-05-14
IL157659A (en) 2008-08-07
DE60221233D1 (de) 2007-08-30
EP1801106A2 (fr) 2007-06-27
AP2003002857A0 (en) 2003-09-30
EP1373224A1 (fr) 2004-01-02
WO2002076953A1 (fr) 2002-10-03
SI1373224T1 (sl) 2007-10-31
KR100617435B1 (ko) 2006-08-31
AR033617A1 (es) 2003-12-26
PT1373224E (pt) 2007-09-25
BR0208192A (pt) 2004-03-02
GEP20053631B (en) 2005-10-10
IL157659A0 (en) 2004-03-28
EE200300459A (et) 2004-02-16
ECSP034750A (es) 2003-10-28
NZ527847A (en) 2005-06-24

Similar Documents

Publication Publication Date Title
SK11562003A3 (sk) Nové spirotricyklické deriváty a ich použitie ako inhibítorov fosfodiesterázy-7
AU2002304800A1 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US7429598B2 (en) Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
CN101198610B (zh) 制备4-[[5-[(环丙基氨基)羰基]-2-甲基苯基]氨基]-5-甲基-N-丙基吡咯并[2,1-f][1,2,4]三嗪-6-甲酰胺的盐的方法及在其中制备的新型稳定形式
CA2701150C (fr) Derives de quinazolinedione, leur preparation et leurs applications therapeutiques
SK160598A3 (en) Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
KR20180088318A (ko) 다중 표적 키나아제 저해제로서 융합피리미딘 유도체
AU2007240176A1 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
JP4772034B2 (ja) 抗ウイルス性4−アミノカルボニルアミノ−置換イミダゾール化合物
TW202411233A (zh) 用於治療trpm3介導病症之新型衍生物
TW200536834A (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
NZ732796A (en) Benzazepine dicarboxamide compounds

Legal Events

Date Code Title Description
FC9A Refused patent application